Literature DB >> 22711853

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

Sigrid Carlsson1, Andrew J Vickers, Monique Roobol, James Eastham, Peter Scardino, Hans Lilja, Jonas Hugosson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22711853      PMCID： PMC3413273          DOI： 10.1200/JCO.2011.40.4327

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  39 in total

1.  Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay.

Authors:  S L Yao; G Lu-Yao
Journal:  J Natl Cancer Inst       Date:  1999-11-17       Impact factor: 13.506

2.  Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

Authors:  Lucy A Brindle; Steven E Oliver; Daniel Dedman; Jenny L Donovan; David E Neal; Freddie C Hamdy; Janet A Lane; Tim J Peters
Journal:  BJU Int       Date:  2006-10       Impact factor: 5.588

3.  Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy--a population-based study.

Authors:  G L Lu-Yao; P Albertsen; J Warren; S L Yao
Journal:  Urology       Date:  1999-08       Impact factor: 2.649

4.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

Authors:  Anthony L Zietman; Michelle L DeSilvio; Jerry D Slater; Carl J Rossi; Daniel W Miller; Judith A Adams; William U Shipley
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

5.  Variations in morbidity after radical prostatectomy.

Authors:  Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

6.  Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).

Authors:  Monique J Roobol; Dina W Roobol; Fritz H Schröder
Journal:  Urology       Date:  2005-02       Impact factor: 2.649

7.  Cancer screening among patients with advanced cancer.

Authors:  Camelia S Sima; Katherine S Panageas; Deborah Schrag
Journal:  JAMA       Date:  2010-10-13       Impact factor: 56.272

8.  An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team.

Authors:  G L Lu-Yao; D McLerran; J Wasson; J E Wennberg
Journal:  JAMA       Date:  1993-05-26       Impact factor: 56.272

9.  Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Authors:  F H Schröder; M Roobol-Bouts; A N Vis; T van der Kwast; R Kranse
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

10.  Short-term effects of population-based screening for prostate cancer on health-related quality of life.

Authors:  M L Essink-Bot; H J de Koning; H G Nijs; W J Kirkels; P J van der Maas; F H Schröder
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506
View more
  47 in total

Review 1.  Serum markers in prostate cancer detection.

Authors:  Ola Bratt; Hans Lilja
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.

Authors:  Aubrey R Turner; Brian R Lane; Dan Rogers; Isaac Lipkus; Kathryn Weaver; Suzanne C Danhauer; Zheng Zhang; Fang-Chi Hsu; Sabrina L Noyes; Tamara Adams; Helga Toriello; Thomas Monroe; Trudy McKanna; Tracey Young; Ryan Rodarmer; Richard J Kahnoski; Mouafak Tourojman; A Karim Kader; S Lilly Zheng; William Baer; Jianfeng Xu
Journal:  Cancer       Date:  2016-07-19       Impact factor: 6.860

3.  Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy.

Authors:  Minoru Kobayashi; Akinori Nukui; Takao Kamai
Journal:  Int J Clin Oncol       Date:  2016-09-08       Impact factor: 3.402

4.  Prostate cancer: Draft USPSTF 2017 recommendation on PSA testing - a sea-change?

Authors:  Theodorus H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2017-06-13       Impact factor: 14.432

Review 5.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Authors:  Katherine Fleshner; Sigrid V Carlsson; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2016-12-20       Impact factor: 14.432

6.  Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era.

Authors:  Sigrid Carlsson; Hans Lilja; Andrew Vickers
Journal:  Eur Urol Focus       Date:  2015-06-09

7.  Perspective on Prostate Cancer Screening.

Authors:  Sigrid V Carlsson; Hans Lilja
Journal:  Clin Chem       Date:  2018-11-20       Impact factor: 8.327

Review 8.  Risk stratification in prostate cancer screening.

Authors:  Monique J Roobol; Sigrid V Carlsson
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

9.  [PSA screening 2013: background and perspectives].

Authors:  F Recker; D Seiler; B Seifert; M Randazzo; M Kwiatkowski
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

10.  Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Authors:  Sigrid V Carlsson; Tiago M de Carvalho; Monique J Roobol; Jonas Hugosson; Anssi Auvinen; Maciej Kwiatkowski; Arnauld Villers; Marco Zappa; Vera Nelen; Alvaro Páez; James A Eastham; Hans Lilja; Harry J de Koning; Andrew J Vickers; Eveline A M Heijnsdijk
Journal:  Cancer       Date:  2016-07-26       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.